Jenkem Technology Overview
- Year Founded
-
2001
- Status
-
Public
- Employees
-
304
- Stock Symbol
-
688356
- Investments
-
4
- Share Price
-
$10.79
- (As of Friday Closing)
Jenkem Technology General Information
Description
Jenkem Technology Co Ltd is engaged in research and development, production and sales of medical polyethylene glycol and its active derivatives. The company's products include Branched polyethylene glycol derivatives; Linear polyethylene glycol derivatives; Double substituted polyethylene glycol derivatives with the same functional group; Heterofunctional double substituted polyethylene glycol derivatives; Multi-arm polyethylene glycol derivatives; Multi-arm heterofunctional double substituted polyethylene glycol derivatives; and Monodisperse Polyethylene Glycol Derivatives.
Contact Information
Website
www.jenkem.comCorporate Office
- 3rd Floor, Building C-1, Zhongguancun Dongsheng Science Park
- No. 66, Xixiaokou Road, Haidian District
- Beijing, 100192
- China
Corporate Office
- 3rd Floor, Building C-1, Zhongguancun Dongsheng Science Park
- No. 66, Xixiaokou Road, Haidian District
- Beijing, 100192
- China
Jenkem Technology Stock Performance
As of 13-Nov-2026, Jenkem Technology’s stock price is $10.79. Its current market cap is $654M with 60.7M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $10.79 | $11.46 | $9.20 - $20.65 | $654M | 60.7M | 5.33M | $0.12 |
Jenkem Technology Financials Summary
As of 30-Sep-2026, Jenkem Technology has a trailing 12-month revenue of $55.3M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 892,564 | 649,043 | 402,470 | 835,942 |
| Revenue | 55,256 | 44,251 | 31,649 | 41,290 |
| EBITDA | 7,888 | 16,066 | 10,781 | 21,717 |
| Net Income | 7,326 | 8,580 | 4,158 | 16,360 |
| Total Assets | 210,130 | 202,679 | 187,293 | 189,819 |
| Total Debt | 830 | 1,017 | 1,859 | 1,243 |
Jenkem Technology Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Jenkem Technology Patents
Jenkem Technology Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20260152751-A1 | Interfering rna for inhibiting jak1 gene expression and use thereof | Pending | 30-May-2024 | ||
| US-20250313844-A1 | Interfering rna for inhibiting pcsk9 gene expression and use thereof | Pending | 09-Apr-2024 | ||
| EP-4768041-A1 | Combination therapy for treating tumors and use thereof | Pending | 15-Sep-2023 | ||
| WO-2025056070-A1 | Combination therapy for treating tumors and use thereof | Inactive | 15-Sep-2023 | ||
| JP-2026526458-A | Foam curing agent composition, method for producing the same, and use | Pending | 13-Jul-2023 | A61K31/765 |
Jenkem Technology Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Jenkem Technology Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Jenkem Technology Investments (4)
Jenkem Technology’s most recent deal was a Secondary Transaction - Private with Salif Bio. The deal was made on 18-May-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Salif Bio | 18-May-2026 | Secondary Transaction - Private | Therapeutic Devices | ||
| DSCi Lab | 23-Oct-2025 | Early Stage VC | Drug Discovery | ||
| Lingel Tech | 15-Sep-2025 | Later Stage VC | Medical Supplies | ||
| Ruitong Bio | 20-Jan-2025 | Early Stage VC | Drug Discovery |
Jenkem Technology ESG
Risk Overview
Risk Rating
Updated January, 31, 2024
31.29 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,201
Rank
Percentile
Pharmaceuticals
Industry
of 863
Rank
Percentile
Pharmaceuticals
Subindustry
of 430
Rank
Percentile
Jenkem Technology FAQs
-
When was Jenkem Technology founded?
Jenkem Technology was founded in 2001.
-
Where is Jenkem Technology headquartered?
Jenkem Technology is headquartered in Beijing, China.
-
What is the size of Jenkem Technology?
Jenkem Technology has 304 total employees.
-
What industry is Jenkem Technology in?
Jenkem Technology’s primary industry is Biotechnology.
-
Is Jenkem Technology a private or public company?
Jenkem Technology is a Public company.
-
What is Jenkem Technology’s stock symbol?
The ticker symbol for Jenkem Technology is 688356.
-
What is the current stock price of Jenkem Technology?
As of 13-Nov-2026 the stock price of Jenkem Technology is $10.79.
-
What is the current market cap of Jenkem Technology?
The current market capitalization of Jenkem Technology is $654M.
-
What is Jenkem Technology’s current revenue?
The trailing twelve month revenue for Jenkem Technology is $55.3M.
-
What is Jenkem Technology’s annual earnings per share (EPS)?
Jenkem Technology’s EPS for 12 months was $0.12.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
